Related Experiment Video
Updated: Aug 5, 2026
08:49
Presynaptic Dopamine Dynamics in Striatal Brain Slices with Fast-scan Cyclic Voltammetry
Published on: January 12, 2012
D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects
Science (New York, N.Y.)
|May 8, 1987
Summary
Concurrent stimulation of D1 and D2 dopamine receptors is required for dopamine-mediated effects on basal ganglia neurons and behavior. This finding challenges the view that D2 receptors alone mediate these responses.
Area of Science:
- Neuroscience
- Pharmacology
- Behavioral Science
Background:
- Dopamine receptors, specifically D1 and D2 subtypes, play crucial roles in regulating basal ganglia function and motor behavior.
- Previous research suggested that D2 dopamine receptors might independently mediate behavioral and neurophysiological changes induced by dopamine agonists.
Purpose of the Study:
- To investigate the synergistic roles of D1 and D2 dopamine receptors in basal ganglia neuronal activity and motor behavior.
- To determine if D2 receptor-mediated effects are dependent on concurrent D1 receptor stimulation by endogenous dopamine.
Main Methods:
- Electrophysiological recordings of basal ganglia neurons in rats.
- Assessment of spontaneous motor activity and stereotyped behaviors.
- Pharmacological manipulation using D1 and D2 dopamine receptor agonists and antagonists.
- Depletion of endogenous dopamine using alpha-methyl-rho-tyrosine.
Main Results:
- The neurophysiological and behavioral effects of D2-selective agonists were significantly attenuated in rats with depleted endogenous dopamine.
- Nonselective dopamine agonists or combinations of D1 and D2 agonists produced robust effects regardless of endogenous dopamine levels.
- These findings indicate that D2 receptor agonist efficacy is dependent on endogenous dopamine acting at D1 receptors.
Conclusions:
- The results challenge the notion that D2 dopamine receptors alone mediate dopamine-induced changes in basal ganglia output and behavior.
- Concurrent stimulation of both D1 and D2 dopamine receptors is necessary for these effects.
- Synergistic interaction between D1 and D2 dopamine receptors is critical for regulating basal ganglia function and motor control.
Related Concept Videos
01:29Drug-Receptor Interactions
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
01:03Dose-Response Relationship: Overview
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:27Adrenergic Neurons: Neurotransmission
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...